학술논문
34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trial
Document Type
Abstract
Author
Source
In ESMO Open February 2023 8(1) Supplement 1
Subject
Language
ISSN
2059-7029